Sanofi Gains Updated FDA Approval for TENIVAC Vaccine

An updated FDA approval letter issued August 26, 2026 for Sanofi Vaccines Canada Ltd's TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) signals that regulatory affairs and biologics compliance teams should conduct a structured review of the revised package insert and supporting documentation before assuming existing labeling and manufacturing conditions remain unchanged.

TENIVAC carries STN# 103171 and is indicated for active immunization against tetanus and diphtheria in persons seven years of age and older. The August 2026 letter is the third approval action on record within the FDA's public docket, following prior letters dated December 16, 2022 and December 6, 2019. Each approval cycle can introduce revised labeling language, updated manufacturing conditions, or modified post-market commitments that carry direct compliance obligations under 21 CFR Part 610 and applicable biologics GMP standards.

For QA directors and regulatory leads managing biologics portfolios, the practical read is straightforward: the updated package insert is now the controlling labeling document. Any internal SOPs, batch release procedures, or distributor-facing materials referencing prior labeling versions require reconciliation against the current insert. Facilities manufacturing or handling TENIVAC under contract arrangements should confirm that their quality agreements reflect the most recent approval conditions.

The public docket also notes that supporting documents older than three years are archived separately, a distinction relevant to teams conducting gap assessments or preparing for FDA biologics establishment inspections where historical approval documentation may be requested.

Regulatory affairs teams should log the August 26, 2026 approval letter against their license maintenance calendars and initiate a labeling change impact assessment to determine whether any downstream submissions, such as updated SPL files or CMC supplements, are required to maintain full compliance posture.

Source: FDA Vaccines, Blood and Biologics via What's New Vaccines Blood Biologics RSS Feed, August 27, 2026.